Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Acquisition

v3.19.3
Note 2 - Acquisition
9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Business Combination Disclosure [Text Block]
Note
2:
Acquisitions
 
On
March 18, 2019,
the Company entered into an Asset and Franchise Purchase Agreement under which (i) the Company repurchased from the seller
one
operating franchise in West Covina, California and (ii) the parties agreed to terminate a
second
franchise agreement for an operating franchise. The Company operates the remaining franchise as a company-managed clinic. The total purchase price for the transaction was
$30,000,
less
$3,847
of net deferred revenue resulting in total purchase consideration of
$26,153.
 
On
July 9, 2019,
the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller
one
operating franchise in Phoenix, Arizona. The Company operates the franchise as a company-owned clinic. The total purchase price for the transaction was
$400,000,
less
$9,835
of net deferred revenue resulting in total purchase consideration of
$390,165.
 
On
July 17, 2019,
the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller
three
operating franchises in Savannah, Georgia, Pooler, Georgia and Bluffton, South Carolina. The Company operates the franchises as company-owned clinics. The total purchase price for the transaction was
$1,604,918,
less
$13,449
of net deferred revenue resulting in total purchase consideration of
$1,591,469.
 
On
August 1, 2019,
the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller
one
operating franchise in Sayebrook, South Carolina. The Company operates the franchise as a company-owned clinic. The total purchase price for the transaction was
$727,414,
less
$5,236
of net deferred revenue resulting in total purchase consideration of
$722,178.
 
On
August 15, 2019,
the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller
one
operating franchise in Chula Vista, California. The Company operates the franchise as a company-managed clinic. The total purchase price for the transaction was
$310,000,
less
$4,328
of net deferred revenue resulting in total purchase consideration of
$305,672.
 
Purchase Price Allocation
 
The following summarizes the aggregate estimated fair values of the assets acquired and liabilities assumed during
2019
as of the acquisition date:
 
 
Property and equipment
 
$
149,542
 
 
 
Operating lease right-of-use asset
 
 
1,219,244
 
 
 
Intangible assets
 
 
1,989,169
 
 
 
Total assets acquired
 
 
3,357,955
 
 
 
Goodwill
 
 
898,031
 
 
 
Deferred revenue
 
 
(123,254
)
 
 
Operating lease liability - current portion
 
 
(208,226
)
 
 
Operating lease liability - net of current portion
 
 
(858,161
)
 
 
Deferred tax liability
 
 
(11,410
)
 
 
Bargain purchase gain
 
 
(19,298
)
 
 
Net purchase price
 
$
3,035,637
 
 
 
Intangible assets in the table above consist of reacquired franchise rights of
$1,479,794
amortized over an estimated useful life of
three
to
four
years and customer relationships of
$509,375
amortized over an estimated useful life of
two
years.
 
Goodwill was established due primarily to synergies and benefits expected to be gained from leveraging the Company’s existing operations and infrastructures, as well as the expected associated revenue and cash flow projections. Goodwill has been allocated to the Company’s Corporate Clinics segment based on such expected benefits. Goodwill related to the acquisition is expected to be deductible for income tax purposes over the next
15
years. The purchase price allocation is preliminary, and the Company expects to finalize the allocation during the
fourth
quarter of
2019.
 
Pro Forma Results of Operations (Unaudited)
 
The following table summarizes selected unaudited pro forma condensed consolidated statements of operations data for the
three
and
nine
months ended
September 30, 2019
and
2018
as if the acquisitions in
2019
had been completed on
January 1, 2018.
 
    Pro Forma for the Three Months Ended   Pro Forma for the Nine Months Ended
    September 30, 2019   September 30, 2018   September 30, 2019   September 30, 2018
Revenues, net   $
12,898,252
    $
9,950,098
    $
35,995,375
    $
28,876,720
 
Net income (loss)   $
596,980
    $
(266,524
)   $
1,837,801
    $
(424,422
)
 
This selected unaudited pro forma consolidated financial data is included only for the purpose of illustration and does
not
necessarily indicate what the operating results would have been if the acquisitions had been completed on that date. Moreover, this information is
not
indicative of what the Company’s future operating results will be. The information for
2018
and
2019
prior to the acquisitions is included based on prior accounting records maintained by the acquired clinics. In some cases, accounting policies differed materially from accounting policies adopted by the Company following the acquisition. For
2018,
this information includes actual data recorded in the Company’s financial statements for the period subsequent to the date of the acquisition. The Company’s condensed consolidated statements of operations for the
three
months ended
September 30, 2019
include net revenue and net loss of approximately
$489,000
and
$1,000,
respectively, attributable to the acquisitions. The Company’s consolidated statements of operations for the
nine
months ended
September 30, 2019
include net revenue and net loss of approximately
$562,000
and
$14,000,
respectively, attributable to the acquisitions.
 
The pro forma amounts included in the table above reflect the application of accounting policies and adjustment of the results of the clinics to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property and equipment and intangible assets had been applied from
January 1, 2018.
The pro forma earnings do
not
include adjustments related to acquisition-related costs incurred in
2019,
which were
not
material.